{
    "nctId": "NCT02961790",
    "briefTitle": "Oxybutynin Chloride in Managing Hot Flashes",
    "officialTitle": "A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ, No Evidence of Disease",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Average Change in Hot Flash Activity Score From Baseline to Week 7 for Low Dose Oxybutynin vs Placebo and for High Dose Oxybutynin vs Placebo",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* History of breast cancer, ductal breast carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS) (currently without evidence of malignant disease) OR a concern about taking estrogen for fear of breast cancer\n* Bothersome hot flashes (defined by their occurrence of \\>= 28 times per week and of sufficient severity to prompt the patient to seek therapeutic intervention)\n* Presence of hot flashes for \\> 30 days prior to study entry\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 0, 1\n* Ability to provide informed written consent\n* Life expectancy \\>= 6 months\n* Willing to work with the enrolling institution for follow-up (during the active monitoring phase of the study)\n\nExclusion Criteria:\n\n* Any of the following current (=\\< 4 weeks prior) or planned therapies:\n\n  * Antineoplastic chemotherapy (anti-HER2 agents allowed)\n  * Androgens\n  * Estrogens (any delivery route)\n  * Progestogens\n  * Tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have been on a constant dose for at least 28 days and must not be expected to stop the medication during the study period\n  * Selective serotonin reuptake inhibitors (SSRIs)/serotonin?norepinephrine reuptake inhibitors (SNRIs), when being used for hot flash management or other indications such as depression, is allowed, assuming the dose will remain unchanged for the study duration\n  * Gabapentin/pregabalin, when being used for hot flash management (use for other indications, such as pain, is allowed, assuming the dose will remain unchanged for the study duration)\n  * Clonidine\n  * Agents with known potent anticholinergic activity; agents with mild-moderate anticholinergic activity are allowed\n* Prior use of oxybutynin during the period in which patient has had hot flashes\n* Pregnant women\n* Nursing women\n* History of any of the following contraindications to oxybutynin:\n\n  * Uncontrolled gastroesophageal reflux disease (GERD) despite appropriate therapy; if patient has history of GERD, but symptoms are well-controlled with medical treatment, patient is eligible\n  * Ulcerative colitis\n  * Narrow-angle glaucoma\n  * Urinary retention\n  * Hypersensitivity to oxybutynin or any other components of the product\n  * Current uncontrolled hyperthyroidism\n  * Coronary heart disease (angina or prior myocardial infarction)\n  * Congestive heart failure\n  * Symptomatic cardiac arrhythmias\n  * Current uncontrolled hypertension\n  * Myasthenia gravis\n  * Dementia",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}